HHS Directs FDA to Stand Down on Unapproved Wellness Peptides

The Department of Health and Human Services acted on Wednesday to allow specialty pharmacies to sell six unapproved injectable peptides, bypassing the Food and Drug Administration’s standard enforcement mechanisms. This directive, issued under Health Secretary Robert F. Kennedy Jr., permits the sale of compounds including BPC-157, TB-500, and KPV, which are marketed for muscle building, injury recovery, and energy enhancement. The policy represents a direct shift in how federal agencies manage the distribution of wellness products that have not undergone rigorous safety or effectiveness reviews.

The administration’s move places the market for these compounds under a new regulatory framework that favors patient access over scientific validation. According to six people familiar with the internal deliberations, FDA scientific staff had minimal input into the final decision and opposed the changes. These individuals, who requested anonymity to discuss confidential government processes, stated that the policy undermines the agency’s historical mission to keep unproven health products off the U.S. market. The new document explicitly directs the FDA to refrain from taking action against pharmacies that sell these specific substances.

Kennedy, who has publicly identified as a fan of peptide therapy and described using BPC-157 for a personal muscle injury, framed the decision as a victory for consumer liberty. In the newly posted document, he stated the change advances patient choice and freedom while shielding Americans from peptides sold online that are often made from unscreened ingredients. The policy serves as a controlled alternative to the black market, according to an HHS spokesperson, by utilizing licensed U.S. compounders. This approach aims to reduce reliance on chemical manufacturers based in China, which often label products as for research use only to avoid regulatory scrutiny.

The financial implications of this shift are substantial for the telehealth and wellness sectors. Wall Street analysts estimate the peptide market could exceed $2 billion. Major players, including Hims & Hers, have already announced plans to offer wellness peptides once government policies aligned with their operational models. Lee Rosebush, a representative of the American Academy of Peptide Medicine, described the HHS action as a huge step for medical freedom. The timing of the announcement, days before the midterm election, has drawn scrutiny from independent observers who view it as a strategic move to appeal to Kennedy’s Make America Healthy Again movement.

The policy deviates from the original HHS plan, which sought to have the FDA draft an official regulation adding these peptides to a list of safe substances for compounding. FDA officials warned that their scientific staff had major safety concerns and would not support a formal regulation deeming the chemicals safe. Consequently, HHS shifted to an enforcement directive that tells the FDA not to enforce its rules against compounding pharmacies. This approach allows the substances to remain technically illegal drugs under FDA rules but permits their sale through a specific channel of licensed pharmacies.

Safety guardrails are included in the new directive, such as requiring pharmacies to source peptide ingredients from FDA-registered factories. Compounders must also collect data on side effects for safety analysis and verify the purity of the materials they use. However, Dr. Peter Lurie, a former FDA official and current head of the Center for Science in the Public Interest, noted that the FDA lacks the federal authority to enforce these specific pharmacy requirements. He argued that the move diverts patients from rigorously tested drugs for conditions like insomnia and anxiety, potentially leading to more unnecessary pain and suffering.

The decision marks a break from the FDA’s recent efforts to limit unproven wellness products. In 2023, the agency added more than a dozen peptides, including BPC-157 and TB-500, to a list of substances that should not be compounded due to risks of allergic reactions, kidney damage, and tumor growth. At a July meeting, FDA staffers reiterated that these peptides remained unproven in terms of safety and effectiveness. Despite this internal consensus, a panel of outside experts selected by Kennedy’s department voted to drop restrictions on the six peptides named in Wednesday’s documents. The panel included doctors, pharmacists, and consultants who work within the peptide industry.

Compounding decisions have historically rested with the FDA, which maintains a dedicated office for protecting consumers from unsafe compounded drugs. This focus intensified after a 2012 outbreak of fungal meningitis linked to contaminated injections from a Massachusetts pharmacy. Since then, compounding has grown into a multibillion-dollar industry. Former FDA officials described it as extremely rare for HHS to lead policy drafting in this sector, although federal law technically grants HHS authority over drug regulations that are then delegated to the FDA.